Abstract
trials due to r Preventive cardiovascular medicine will get a big boost from ongoing major randomized controlled eport results during the next several years, Eric D. Peterson, MD, MPH, predicted at the annual meeting of the American College of Cardiology in San Diego. He presented an overview of eagerly anticipated clinical trials approaching completion in three of the hottest areas of research in general cardiology: new cardiovascular disease prevention agents and strategies; innovative health policy initiatives; and optimal antithrombotic regimens across the range of chronic coronary artery disease, peripheral arterial disease, patients with atrial fibrillation who’ve undergone percutaneous coronary intervention, and cerebrovascular disease. Dr. Peterson is executive director of the Duke Clinical Research Institute (DCRI), and professor of medicine at Duke University in Durham, N C.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
